Cencora, Inc. $COR Stake Reduced by Harel Insurance Investments & Financial Services Ltd.

Harel Insurance Investments & Financial Services Ltd. cut its stake in Cencora, Inc. (NYSE:COR) by 4.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,016 shares of the company’s stock after selling 796 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in Cencora were worth $5,702,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. DAVENPORT & Co LLC grew its position in shares of Cencora by 12.8% during the first quarter. DAVENPORT & Co LLC now owns 6,214 shares of the company’s stock worth $1,728,000 after acquiring an additional 705 shares during the last quarter. Keybank National Association OH boosted its stake in Cencora by 1.7% during the 1st quarter. Keybank National Association OH now owns 8,034 shares of the company’s stock valued at $2,234,000 after purchasing an additional 133 shares during the period. Pinnacle Financial Partners Inc bought a new position in Cencora in the 1st quarter worth about $253,000. Private Trust Co. NA increased its stake in shares of Cencora by 2.5% in the first quarter. Private Trust Co. NA now owns 1,933 shares of the company’s stock valued at $538,000 after purchasing an additional 47 shares during the period. Finally, D.A. Davidson & CO. raised its holdings in shares of Cencora by 3.4% during the first quarter. D.A. Davidson & CO. now owns 1,909 shares of the company’s stock valued at $531,000 after buying an additional 63 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Wells Fargo & Company increased their price objective on Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a report on Wednesday, August 13th. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Morgan Stanley set a $330.00 price target on Cencora and gave the company an “equal weight” rating in a report on Wednesday, July 16th. Weiss Ratings restated a “buy (b-)” rating on shares of Cencora in a research note on Thursday. Finally, UBS Group increased their target price on shares of Cencora from $350.00 to $380.00 and gave the company a “buy” rating in a research report on Monday, October 27th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $329.55.

Cencora Stock Down 1.1%

COR opened at $337.60 on Friday. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The company has a market capitalization of $65.45 billion, a PE ratio of 34.73, a P/E/G ratio of 1.56 and a beta of 0.63. The stock’s fifty day moving average is $308.09 and its 200-day moving average is $297.11. Cencora, Inc. has a one year low of $223.92 and a one year high of $350.46.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.21. The business had revenue of $80.66 billion during the quarter, compared to analysts’ expectations of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company’s quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the business posted $3.34 earnings per share. On average, equities analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.7%. Cencora’s payout ratio is currently 22.63%.

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the sale, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 41,544 shares of company stock worth $12,230,941 over the last quarter. Insiders own 10.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.